Cover Image
市場調查報告書

全球ADHD治療藥市場:專利失效的同時,隨著診斷標準的擴張·成人患病者的增加持續成長市場

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

出版商 GBI Research 商品編碼 310993
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
全球ADHD治療藥市場:專利失效的同時,隨著診斷標準的擴張·成人患病者的增加持續成長市場 ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations
出版日期: 2014年07月31日 內容資訊: 英文 91 Pages
簡介

近年來,由於ADHD(注意力不足過動症(簡稱過動症))的診斷基準擴張及緩和,被診斷出ADHD的成人也日益增加。推計美國成人有4.1%發病,其中41.3%嚴重患者必須接受治療。目前ADHD治療藥市場充滿了學名藥,斷乎所有藥品都是把即放性(IR)藥劑改作緩釋型(ER)。但大部分藥劑也都伴隨著濫用的危險性。此外,針對不適用刺激藥的患者,也在開發非刺激性治療藥。今後比起新藥的認証,在診斷率上升、患者數增加的背景下,一般認為ADHD治療藥市場將會持續擴大,到2020年前將以年平均成長率(CAGR)4.8%成長,並在該年達到94億美金的市場規模。

本報告提供全球各國注意力不足過動症(簡稱過動症)(ADHD)治療方法的相關市場分析,提供您疾病概要和主要的治療模式,已上市產品概要(安全性·功效等),現在正在開發的治療藥的開發平台資訊,全球及主要國家的市場趨勢預測(今後8年的預測值),資本交易·產業聯盟的動向等。

第1章 目錄

第2章 簡介

  • 疾病概要
  • 症狀
  • 流行病學
  • 病因
  • 病理生理學
    • 診斷標準規模
    • DSM-5ADHD的標準
    • ICD-10過動症的標準
  • 治療方法
    • 治療流程

第3章 已上市產品

  • 刺激藥
    • Adderall XR (Shire)
    • Concerta (Janssen Pharmaceuticals)
    • Daytrana (Noven Pharmaceuticals)
    • Focalin XR (Novartis)
    • Ritalin LA (Novartis)
    • Provigil (Teva Pharmaceutical)
    • Quillivant XR (Pfizer Pharmaceuticals)
    • Vyvanse (Shire)
  • 刺激藥以外
    • Strattera (Eli Lilly)
    • Intuniv (Shire)
    • Kapvay (Concordia Pharmaceuticals)
  • 功效·安全性比較分析

第4章 ADHD用開發中產品

  • 概要
  • 開發中產品的運作機制
  • 臨床實驗
    • 損耗率
    • 臨床實驗期間
    • 臨床實驗的規模
    • 臨床實驗相關指標比較分析
    • SHP465 (Shire)
    • NT-0202 (Neos Therapeutics)
    • Edivoxetine (Eli Lilly)
    • NWP09 (Pfizer)
    • NT-0102 (Neos Therapeutics)
    • metadokishin的ER(長效緩釋) (Alcobra)
    • SPN-812 (Supernus Pharmaceuticals)
    • dekisutoroanfetamin的經皮給藥 (Noven Pharmaceuticals)
  • 功效·安全性比較分析

第5章 市場未來預測

  • 全球市場
  • 北美
    • 治療方法的利用模式
    • 年度治療費用
    • 市場規模
  • 歐洲主要5個國家(EU5)
  • 日本
  • 推動及阻礙市場要素

第6章 資本交易與策略性市場重組

  • 概要
  • 共同開發契約

第7章 附錄

圖表一覽

目錄
Product Code: GBIHC337MR

GBI Research has released the pharma report, "ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations" Changes in diagnostic criteria have reduced the symptom threshold for diagnosis and finally bring the acceptance of adult ADHD to the clinical setting, enabling those previously unable to obtain a diagnosis to be diagnosed for ADHD treatment. In the case of adult ADHD, 4.1% of US adults are believed to suffer from ADHD, 41.3% of these cases are classified as severe and would be eligible for therapeutic intervention.

The current ADHD therapeutics market is flooded with generics and dominated by the use of Extended-Release (ER) stimulant drugs which have superseded short-acting, Immediate-Release (IR) formulations. With dose titration per patient, ER stimulants are usually effective in 70-90% of patients. However, all stimulants apart from Vyvanse come with potential for abuse. Non-stimulants are used for those who are poor-responders, have poor cardiac history or prefer non-stimulant medication however their efficacy is lacking in comparison. Currently, 10% of adult patients are using a combination of ER and IR treatment for an additional duration, representing an unmet need within this growing ADHD segment.

The current developmental pipeline addresses these gaps in the market, with three potential non-stimulants entering the market during the forecast period and SHP465, which aims to address the unmet need in the adult ADHD segment with its tailored duration of action. In spite of anticipated drug approvals, patents expirations and increased generic competition will cause ACoT to remain fairly static and even decrease across some nations.

As a result, the global market is not expected to be driven by drug approvals, but primarily by a growing prevalence, increase in rates of diagnosis, and therefore eligible treatment population. Global market revenues are forecast to rise at a CAGR of 4.8% to $9.4 billion by 2020.

Scope

The report analyzes the incidence of ADHD, current options for its treatment, pipeline, market forecasts and deals surrounding ADHD therapeutics.The report covers and includes -

  • A brief introduction into ADHD, symptoms, diagnosis, epidemiology, etiology, pathophysiology, economic implications of their treatment and the current treatment options for the condition.
  • An analysis of the currently marketed ADHD drugs, including recent sales figures, safety and efficacy data of the drugs and a discussion of the likely performance of each drug within the forecast period.
  • Comprehensive reviews of the pipeline for ADHD drugs, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule type and mechanism of action.
  • Additional statistical analysis of clinical trial duration, size and attrition rate by phase and mechanism of action.
  • An in-depth, multi-scenario forecast model for the ADHD drugs market in the US, Canada, UK, France, Germany, Italy, Spain and Japan. Each model is based on the anticipated performance of both marketed drugs and any expected to be approved within the forecast period, and takes into account drug cost, patent expiration, efficacy, safety and likely prescription volumes.
  • A detailed discussion of drivers and barriers for the ADHD market
  • An in-depth analysis of licensing and co-development deals involving drugs indicated in ADHD, including an in-depth outline of key deals.

Reasons to buy

  • The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to -
  • Understand the key signaling pathways and molecular targets currently under investigation in drug development for ADHD.
  • Gain an in-depth view of the current status of the ADHD therapeutics pipeline, including the most common molecule types and molecular targets in development.
  • Observe trends in clinical trial duration and size amongst clinical phases and mechanisms of action, and use the clinical trial attrition rate analysis to assess the risk profiles of current and/or future developmental programs for ADHD therapeutics.
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the ADHD therapeutics market.
  • Analyze current and past deals surrounding ADHD therapeutics, including their value, year of deal and in-depth details of key deals within the ADHD market.

Abstract

The Attention-Deficit Hyperactivity Disorder (ADHD) therapeutics market value will rise from $6.9 billion in 2013 to $9.9 billion by 2020, with broadening diagnostic criteria a key driver of growth, according to business intelligence provider GBI Research.

The company's latest report* states that this increase, which represents a Compound Annual Growth Rate (CAGR) of 5.3% and relates to eight major markets (the US, the UK, France, Germany, Spain, Italy, Japan and Canada), will occur fastest in Japan, due to its high ADHD prevalence.

Despite the stigma attached to mental health conditions, this country will witness a more impressive ADHD treatment market CAGR of 15.7%.

Dale Prior, Analyst for GBI Research, says: "ADHD prevalence will rise steadily across the major markets, from approximately 15 million cases in 2013 to just over 18 million by 2020. However, diagnosis rates are particularly low outside of the US, as the disorder is still treated with considerable skepticism.

"Debate remains about the fear of under- or over-diagnosis, the causes and legitimacy of ADHD as a condition, and the skew towards greater prevalence in the US. Research has suggested that ADHD is just as prevalent in other countries as in the US, but it is significantly more recognized in this market."

Prior notes that this trend is expected to change over the coming decade, due largely to an increased recognition of adult ADHD.

The fifth edition of The Diagnostic and Statistical Manual of Mental Disorders, which was published in 2013, broadened the diagnostic criteria for ADHD, recognizing that impairment from symptoms of the disorder may develop in later life.

Prior comments: "These developments herald the final acceptance of adult ADHD in a clinical setting and mean that many people who met the 'partial remission' criteria will now meet the full criteria, leading to an increase in diagnosis.

"However, the continuing reluctance of many patients to seek treatment for mental health conditions will be a barrier to ADHD diagnosis rates, and consequently to any further market growth."

ADHD therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

This report provides analysis of the currently marketed Attention-Deficit Hyperactivity Disorder (ADHD) drugs, including recent sales figures and safety and efficacy data, across eight major markets (8MM: the US, Canada, UK, France, Germany, Italy, Spain and Japan). It also provides comprehensive reviews of the ADHD drugs pipeline and in-depth, multi-scenario forecasts for ADHD therapeutics in the 8MM up to 2018.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Symptoms
  • 2.3. Epidemiology
  • 2.4. Etiology
  • 2.5. Pathophysiology
    • 2.5.1. Diagnosis Rating Scales
    • 2.5.2. DSM-5 Criteria for ADHD
    • 2.5.3. ICD-10 Criteria for Hyperkinetic Disorder
  • 2.6. Treatment
    • 2.6.1. Treatment Algorithm

3. Marketed Products

  • 3.1. Stimulant Drugs
    • 3.1.1. Adderall XR - Shire
    • 3.1.2. Concerta - Janssen Pharmaceuticals
    • 3.1.3. Daytrana - Noven Pharmaceuticals
    • 3.1.4. Focalin XR - Novartis
    • 3.1.5. Ritalin LA - Novartis
    • 3.1.6. Provigil - Teva Pharmaceutical
    • 3.1.7. Quillivant XR- Pfizer Pharmaceuticals
    • 3.1.8. Vyvanse - Shire
  • 3.2. Non-stimulant Drugs
    • 3.2.1. Strattera - Eli Lilly
    • 3.2.2. Intuniv - Shire
    • 3.2.3. Kapvay - Concordia Pharmaceuticals
  • 3.3. Comparative Efficacy and Safety

4. ADHD Pipeline

  • 4.1. Overview
  • 4.2. Mechanisms of Action in the Pipeline
  • 4.3. Clinical Trials
    • 4.3.1. Attrition Rate
    • 4.3.2. Clinical Trial Duration
    • 4.3.3. Clinical Trial Size
    • 4.3.4. Comparative Clinical Trial Metrics Analysis
    • 4.3.5. SHP465 - Shire
    • 4.3.6. NT-0202 - Neos Therapeutics
    • 4.3.7. Edivoxetine - Eli Lilly
    • 4.3.8. NWP09 - Pfizer
    • 4.3.9. NT-0102 - Neos Therapeutics
    • 4.3.10. Metadoxine ER - Alcobra
    • 4.3.11. SPN-812 - Supernus Pharmaceuticals
    • 4.3.12. Dextroamphetamine Transdermal - Noven Pharmaceuticals
  • 4.4. Comparative Efficacy and Safety

5. Market Forecast to 2020

  • 5.1. Global Market
  • 5.2. North America
    • 5.2.1. Treatment Usage Patterns
    • 5.2.2. Annual Cost of Treatment
    • 5.2.3. Market Size
  • 5.3. Leading Five EU Countries (EU5)
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Treatment
    • 5.3.3. Market Size
  • 5.4. Japan
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Treatment
    • 5.4.3. Market Size
  • 5.5. Drivers and Barriers
    • 5.5.1. Drivers
    • 5.5.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Overview
  • 6.2. Co-development Deals

7. Appendix

  • 7.1. Market Definition
  • 7.2. Abbreviations
  • 7.3. References
  • 7.4. Research Methodology
    • 7.4.1. Secondary Research
    • 7.4.2. Marketed Product Profiles
    • 7.4.3. Late-Stage Pipeline Candidates
    • 7.4.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 7.4.5. Product Competitiveness Framework
    • 7.4.6. Pipeline Analysis
    • 7.4.7. Forecasting Model
    • 7.4.8. Deals Data Analysis
  • 7.5. Contact Us
  • 7.6. Disclaimer

List of Tables

  • Table 1: Common Assessment Scales Used to Aid ADHD Diagnosis
  • Table 2: DSM-5 Criteria for Attention Deficit Hyperactivity Disorder
  • Table 3: ICD-10 Criteria for Attention Deficit Hyperactivity Disorder
  • Table 4: ADHD Therapeutics Market, Global, Pipeline, Discovery, 2014
  • Table 5: ADHD Therapeutics Market, Global, Pipeline, Preclinical, 2014
  • Table 6: ADHD Therapeutics Market, Global, Pipeline, Phase I, 2014
  • Table 7: ADHD Therapeutics Market, Global, Pipeline, Phase II, 2014
  • Table 8: ADHD Therapeutics Market, Global, Pipeline, Phase III, 2014
  • Table 9: ADHD Theapeutics Market, Global, Pipeline, Pre-Registration, 2014
  • Table 10: ADHD Therapeutics Market, Global, Market Forecast, 2013-2020
  • Table 11: ADHD Therapeutics Market, US, Market Forecast, 2013-2020
  • Table 12: ADHD Therapeutics Market, Canada, Market Forecast, 2013-2020
  • Table 13: ADHD Therapeutics Market, UK, Market Forecast, 2013-2020
  • Table 14: ADHD Therapeutics Market, France, Market Forecast, 2013-2020
  • Table 15: ADHD Therapeutics Market, Germany, Market Forecast, 2013-2020
  • Table 16: ADHD Therapeutics Market, Italy, Market Forecast, 2013-2020
  • Table 17: ADHD Therapeutics Market, Spain, Market Forecast, 2013-2020
  • Table 18: ADHD Therapeutics Market, Japan, Market Forecast, 2013-2020

List of Figures

  • Figure 1: ADHD Treatment Algorithm
  • Figure 2: ADHD Therapeutics Market, Marketed Products, Heat Map, 2013
  • Figure 3: ADHD Therapeutics Market, Global, Pipeline (%), 2013
  • Figure 4: ADHD Therapeutics Market, Global, Pipeline Distribution by Mechanism of Action and Program Type, 2013
  • Figure 5: ADHD Therapeutics Market, Global, Pipeline Distribution by Mechanism of Action (Tier 1) and Stage of Development, 2013
  • Figure 6: ADHD Therapeutics Market, Global, Pipeline Distribution by Mechanism of Action (Tier 2) and Stage of Development, 2013
  • Figure 7: ADHD Therapeutics Market, Global, Pipeline, Attrition Rate (%), 2013
  • Figure 8: ADHD Therapeutics Market, Global, Attrition Rate by Mechanism of Action (%), 2013
  • Figure 9: ADHD Therapeutics Market, Global, Pipeline, Clinical Trial Duration (months), 2013
  • Figure 10: ADHD Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism (months), 2013
  • Figure 11: ADHD Therapeutics Market, Global, Pipeline, Clinical Trial Size, 2013
  • Figure 12: ADHD Therapeutics Market, Global, Pipeline, Clinical Trial Size per Product by Mechanism of Action, 2013
  • Figure 13: ADHD Therapeutics Market, Global, Pipeline, Size by Clinical Trial by Mechanism of Action, 2013
  • Figure 14: ADHD Therapeutics Market, Global, Pipeline, Mechanism of Action Heat Map, 2013
  • Figure 15: ADHD Therapeutics Market, Global, Sales Forecast for Edivoxetine ($m), 2016-2020
  • Figure 16: ADHD Therapeutics Market, Global, Sales Forecast for Metadoxine ER ($m), 2017-2020
  • Figure 17: ADHD Therapeutics Market, Global, Sales Forecast for SPN-812 ($m), 2019-2020
  • Figure 18: ADHD Therapeutics Market, Promising Pipeline Molecules, Heat Map
  • Figure 19: ADHD Therapeutics Market, Marketed Products, Heat Map, 2013
  • Figure 20: ADHD Therapeutics Market, Global, Treatment Patterns (million), 2013-2020
  • Figure 21: ADHD Therapeutics Market, Global, Market Size ($bn), 2013-2020
  • Figure 22: ADHD Therapeutics Market, Global, 2013-2020
  • Figure 23: ADHD Therapeutics Market, North America, Treatment Patterns, 2013-2020
  • Figure 24: ADHD Therapeutics Market, North America, Annual Cost of Treatment ($), 2013-2020
  • Figure 25: ADHD Therapeutics Market, North America, Market Size ($m), 2013-2020
  • Figure 26: ADHD Therapeutics Market, Top Five EU Countries, Treatment Patterns, 2013-2020
  • Figure 27: ADHD Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2013-2020
  • Figure 28: ADHD Therapeutics Market, Top Five EU Countries, Market Size ($m), 2013-2020
  • Figure 29: ADHD Therapeutics Market, Japan, 2013-2020
  • Figure 30: ADHD Therapeutics Market, Global, Major Licensing Deals by Year and Value, 2006-2014
  • Figure 31: ADHD Therapeutics Market, Global, Major Licensing Deals, 2006-2014
  • Figure 32: ADHD Therapeutics Market, Global, Major Co-developments Distribution, 2006-2014
  • Figure 33: ADHD Therapeutics Market, Global, Major Co-developments by Year and Phase, 2006-2014
Back to Top